From: Jan Drew on
http://www.putchildrenfirst.org/flu.html

Flu Vaccine Facts
From: Carole on

"Jan Drew" <jdrew1374(a)sbcglobal.net> wrote in message
news:r2XCk.1503$Ws1.1418(a)nlpi064.nbdc.sbc.com...
> http://www.putchildrenfirst.org/flu.html
>
> Flu Vaccine Facts

Good one Jan

Eli Lilly Material Data Safety Sheet for Thermisoral (mercury)
http://www.putchildrenfirst.org/media/6.18.pdf

Effects of Overexposure: Topical allergic dermatitis has been reported.
Thimerosal contains
mercury. Mercury poisoning may occur and topical hypersensitivity reactions
may be seen. Early signs
of mercury poisoning in adults are nervous system effects, including
narrowing of the visual field and
numbness in the extremities. Exposure to mercury in utero and in children
may cause mild to severe
mental retardation and mild to severe motor coordination impairment. Based
on animal data, may be
irritating to the eyes.

carole
www.cellsalts.net


From: Jan Drew on

"Carole" <hubbca(a)iimetro.com.au> wrote in message
news:fgPDk.1483$sc2.1211(a)news-server.bigpond.net.au...
>
> "Jan Drew" <jdrew1374(a)sbcglobal.net> wrote in message
> news:r2XCk.1503$Ws1.1418(a)nlpi064.nbdc.sbc.com...
>> http://www.putchildrenfirst.org/flu.html
>>
>> Flu Vaccine Facts
>
> Good one Jan
>
> Eli Lilly Material Data Safety Sheet for Thermisoral (mercury)
> http://www.putchildrenfirst.org/media/6.18.pdf
>
> Effects of Overexposure: Topical allergic dermatitis has been reported.
> Thimerosal contains
> mercury. Mercury poisoning may occur and topical hypersensitivity
> reactions may be seen. Early signs
> of mercury poisoning in adults are nervous system effects, including
> narrowing of the visual field and
> numbness in the extremities. Exposure to mercury in utero and in children
> may cause mild to severe
> mental retardation and mild to severe motor coordination impairment. Based
> on animal data, may be
> irritating to the eyes.
>
> carole
> www.cellsalts.net
>
>
Always my pleasure to post the truth.
Got lots more about Eli Lilly.

http://groups.google.com/group/misc.health.alternative/msg/a7503575659f780e?hl=en


http://www.mercola.com/2007/jan/6/what-company-covered-up-the-health-risks-of-its-top-selling-drug-for-a-decade.htm

What Company Covered up the Health Risks of its Top-Selling Drug for a
Decade?

Hundreds of internal company documents and e-mails suggest that Eli Lilly
covered up concerns about its schizophrenia drug Zyprexa, though the company
insists it did not. The evidence was obtained from an attorney representing
patients in a lawsuit.
The documents suggest that, over the 10 years the drug has been on the
market, the company withheld important information about the drug's links to
obesity and increases in blood sugar levels. Both of these symptoms can
increase the risk of diabetes.

Zyprexa sales exceeded $4 billion last year, and more than 20 million have
used the drug. It is widely prescribed to deal with schizophrenia and
bipolar disorder.

New York Times December 17, 2006

Yahoo News December 17, 2006

Consumer Affairs December 18, 2006



--------------------------------------------------------------------------------

Dr. Mercola's Comment:


Evista isn't the only drug that will cause embarrassing problems this year
for Eli Lilly. The drugmaker concocted a decade-long scam to protect its
number one seller, Zyprexa, according to this New York Times piece.

Diabetes can eliminate 15 years from your life. With such serious risks on
the table you would expect a company to protect the interests of its end
users. Unfortunately, this just doesn't seem to be the case with most drug
companies; they are far more committed to their corporate profits than the
benefits to those that purchase their products.

Lilly denies any wrongdoing. In fact, they reminded their drug sales
force -- who try to keep your bathroom cabinets full of drugs you don't
need -- to conveniently play down reports Zyprexa had been responsible for
patients gaining 100 pounds or more after taking it.

And if you wonder why Lilly has been so focused on protecting Zyprexa, a
month's supply of the older perphenazine is $60, while Zyprexa costs more
than $500 for a comparable supply.

On Vital Votes, reader Daniel from Bangor, Maine reports on another piece of
the Zyprexa scandal:

"Zyprexa off label promotion scandal is all over the news now. Lilly drug
reps are alleged to have called their marketing ploy, 'Viva zyprexa'.

"Eli Lilly zyprexa cost me over $250.00 a month supply out of my own pocket
X 4 years and has up to ten times the risk (over non users) of causing
diabetes and severe weight gain.

"Zyprexa which is only FDA approved for schizophrenia (.5-1% of pop) and
some bipolar (2% pop) ... So how does Zyprexa get to be the 7th largest drug
sale in the world? Eli Lilly is in deep trouble for using their drug reps to
'encourage' doctors to write zyprexa for non-FDA approved 'off label' uses.

"The drug causes increased diabetes risk, and medicare picks up all the
expensive fallout. There are now 7 states (and counting) going after Lilly
for fraud and restitution."

Other responses to this article can be viewed at Vital Votes, and you can
add your own thoughts or vote on comments by first registering at Vital
Votes.




Related Articles:


Eli Lilly Slapped for Off-Label Drug Use

Drugging America's Children With Anti-Psychotics

Diabetes Link to Anti-Psychotic Drug Zyprexa



http://www.24-7pressrelease.com/view_press_release.php?rID=9094&tf7sid=d1befd96efe53fd095aa9640406555ae

RITALIN - THE COVER-UP OF SUICIDES
TREATMENT WITH RITALIN HAS CAUSED SUICIDES AND SUICIDE ATTEMPTS IN CHILDREN.
"21 CASES OF ATTEMPTED SUICIDE AND SIX SUICIDES" - SWEDISH MEDICAL AGENCY
APPROVED RITALIN ANYWAY. FDA HAS WARNED ABOUT "SUICIDE IDEATION" IN
CONNECTION WITH RITALIN TREATMENT - DIDN'T FDA KNOW ABOUT THE SUICIDES?



/24-7PressRelease/ - SWEDEN, October 29, 2005 - From the depths of the
archives at the Swedish Medical Products Agency (MPA) some astonishing
papers have emerged. Papers showing that Ritalin, prescribed to children
with the diagnosis ADHD, causes depression and has led to suicides and
suicide attempts.

The MPA knew about these disastrous effects when approving Ritalin for sales
in Sweden June 15 this year. No warnings were given to physicians or the
public.

FDA announced June 28 that Ritalin and other methylphenidate drugs had been
linked to "visual hallucinations, suicidal ideation, psychotic behavior, as
well as aggression or violent behaviour". Nothing was said about suicides or
suicide attempts.

The narcotic drug Ritalin has been withdrawn from the Swedish market for 37
years - since the abuse catastrophe in the 60-ties. But Swedish
psychiatrists have in recent years demanded the right to prescribe Ritalin
and other stimulants to children - with the false pretence that the narcotic
drug for children with the diagnosis ADHD would work as insulin for persons
with diabetes. The expert child psychiatrist at the MPA has led the
campaign; he has assured the public there are no serious short-term or
long-term side effects from stimulant treatment of children.

When the British pharmaceutical company GlaxoSmithKline (GSK) 2003 tried to
get approval for children for its blockbuster drug Seroxat (Paxil) it was
revealed that the company already five years earlier had known that the drug
increased the suicide risk in children. This exposure led to the disapproval
of the application and the British authorities instead banned Seroxat -
should not be prescribed to children.

History seemed to be repeating itself when pharmaceutical company Novartis
in 2004 was seeking approval for Ritalin for children in Sweden - a country
in the unique position of having banned the drug already in the 60-ties.
Novartis had not for many years had reason to turn in documentation in other
countries, but they had to do it in Sweden. And in the submitted documents
(written already year 2000!) it is under the heading SUICIDE revealed: "it
is known that Ritalin therapy and its sudden discontinuation may cause
depression in some patients..."

Under the same heading Novartis is also revealing: "A search of the Novartis
international safety data base allowed the identification of 21 cases of
attempted suicide and six suicides, in addition to 25 reports of suicidal
ideations in patient aged 6-48 years, 56% of whom were children aged less
than 16 years."

But unlike the British authorities in the Seroxat case the Swedish MPA
didn't come to the defence of the children. Instead the MPA in June 2005
approved Ritalin, and covered up the information about suicides and suicide
attempts! The public or physicians didn't get any warnings.

And now the MPA has taken one step further: declared that the document
telling about the suicides is classified information. It is decided, "the
pharmaceutical company in question can be harmed" if access is granted to
the documentation.

The agency supposed to be for the public is, under pressure from
psychiatrists and a pharmaceutical company, approving a narcotic drug that
can cause depression and suicide. It is then hiding the disastrous results
to protect the company.

This medical scandal also involves the FDA. The agency can be expected to
have known about the deadly effects of Ritalin - but did not act. What is
buried in the files of the FDA?


http://www.24-7pressrelease.com/view_press_release.php?rID=12752&tf7sid=d1befd96efe53fd095aa9640406555ae

Eli Lilly withheld disastrous effects of Strattera from parents and children
The wording of the parent and children information in an ongoing clinical
trial of Strattera has been revealed. Eli Lilly withheld the drug's
disastrous effects in order to get children to participate in the study.



http://www.laleva.org/eng/2006/01/eli_lilly_internal_documents_lilly_knew_about_prozac_induced_suicidality.html

Eli Lilly Internal Documents - Lilly Knew About Prozac Induced Suicidality

January 9, 2005
Baum - Hedlund
www.baumhedlundlaw.com

Below is the time-line presented to the jury in the Forsyth v. Eli Lilly
Trial. It was presented during closing arguments by the plaintiffs. It lists
Lilly's internal documents. The plaintiffs allege that it shows that Lilly
knew about Prozac-induced suicidality and violence (even before Prozac was
approved for marketing in the United States) and that this was withheld from
the public.

1) Aug. 1978 - Team Meeting Minutes - "There have been a fairly large number
of reports of adverse reactions . . . Another depressed patient developed
psychosis . . . Akathisia and restlessness were reported in some patients."
Exhibit 30 (2nd page, end of 2nd paragraph)

2) May 1984 - BGA Comments - "During the treatment with the preparation
(Prozac) 16 suicide attempts were made, 2 of these with success. As patients
with a risk of suicide were excluded from the studies, it is probable that
this high proportion can be attributed to an action of the preparation
(Prozac) . . ." Exhibit 42 (page 3, 6th paragraph)

3) Jan. 1985 - Lilly receives reasons why the BGA will reject Lilly
registration, one of which was because of "SUICIDAL RISK." With instructions
for "IMMEDIATE FOLLOW-UP ON ALL KEY OPINION LEADERS ON THE BGA COMMISSION
FOR SELECTED VISITATION NEXT WEEK." Exhibit 53

4) March 29, 1985 - "Benefit/Risk Considerations" - "The incidence rate
(suicide) under fluoxetine (Prozac) therefore purely mathematically is 5.6
times higher than under the other active medication imipramine." . . . "The
benefits vs. risks considerations for fluoxetine (Prozac) currently does not
fall clearly in favor of the benefits. Therefore, it is of the greatest
importance that it be determined whether there is a particular subgroup of
patients who respond better to fluoxetine (Prozac) than to imipramine, so
that the higher incidence of suicide attempts may be tolerable." Exhibit 58
(pages 18 & 22)

5) June 1986 - Draft of Proposed PRECAUTIONS and ADVERSE REACTIONS Sections
of the Prozac Package Insert - "Mania and psychosis may be precipitated in
susceptible patients by antidepressant therapy." Exhibit 5 (1st page) (never
included in actual inserts)

6) Aug. 1989 - Additional Feedback Regarding the Fluoxetine (Prozac) Review
by the Commission A (Germany) - "3. The counterindication because of acute
suicidality should become a warning whereby the physicians should be advised
that in the absence of sedation, the risk of higher suicidality should be
taken into account." Exhibit 88

7) Nov. 17, 1989 - Letter to sales representatives on article about
Prozac-induced akathisia authored by Dr. Lipinski and others. "In the
article the authors voice their suspicion that 'the triad of symptoms'
(anxiety, nervousness, and insomnia) reflects the syndrome of akathisia,
'which, in their view is apparently related to fluoxetine (Prozac) therapy."
But the sales people are warned: "Use of this information in product
discussions may violate federal law." Exhibit 91 (1st page, 2nd paragraph
and 2nd page, last sentence)

8) Jan. 1990 - PROZAC and SELF-DIRECTED VIOLENCE - "We have just received a
pre-print of an article (not a letter to ed.) Which we understand is to
appear in the February 1990 AMERICAN JOURNAL OF PSYCHIATRY suggesting that
Prozac can induce severe, intense, obsessional suicidal ideation." . . ."
Exhibit 94

9) Jan. 30, 1990 - Letter to sales representatives giving the sales people a
"heads-up" on the forthcoming Teicher article regarding Prozac and Suicide
and instructing them as follows: "Because these issues (suicide) are not
part of our current marketing plan, you should not initiate discussions on
these articles. ... "Again, because these issues are not part of our current
marketing plan, discussions should not be initiated by you." Exhibit 15
(bottom of second page)

10) Feb 1990 - Teicher article published "Emergence of Intense Suicidal
Preoccupation During Fluoxetine (PROZAC) Treatment" - "The purpose of this
report is to suggest the surprising possibility that fluoxetine (Prozac) may
induce suicidal ideation in some patients." . . . "In our experience, this
side effect has occurred in 3.5% of patients receiving fluoxetine (Prozac) .
.. ." Exhibit 95

11) February 7, 1990 - Leigh Thompson Memo - "Anything that happens in the
UK (England) can threaten this drug (Prozac) in the US and worldwide. We are
now expending enormous efforts fending off attacks because of (1)
relationship to murder and (2) inducing suicidal ideation." Exhibit 97

12) February 7, 1990 - Leigh Thompson Memo - "I am concerned about reports I
get re UK attitude toward Prozac safety. Leber (FDA) suggested a few minute
ago we using CSM database to compare Prozac aggression and suicidal ideation
with other antidepressants in UK. Although he is a fan of Prozac and
believes a lot of this is garbage, he is clearly a political creature and
will have to respond to pressures. I hope Patrick realizes that Lilly can go
down the tubes if we lose Prozac and just one event in the UK can cost us
that." Exhibit 98

13) June 1990 - Letter to Lilly by concerned doctor - "I am writing to
inform Eli Lilly Company that a disturbing number of suicides or suicide
attempts associated with Prozac has come to my attention over the last
several months." I am concerned that the association with Prozac may be more
than coincidental." . . . "There appears to be growing concern that Prozac
may somehow trigger a suicidal preoccupation in a small subset of patients
and that their families should be warned of this potential risk. It is
certainly possible that some of the cases reported are "coincidence" in that
the depressed person may have attempted suicide independently of Prozac.
However, some of these cases appear to be in patients taking Prozac for
reasons other than depression." Exhibit 102 (2nd page)

14) July 18, 1990 - Memo regarding call from Paul Leber at the FDA. "Paul
Leber called yesterday; I contacted him at 6:15 am this morning and
half-hour conversation, very, very pleasant . . ." "The call was about
suicide." . . . "He asked that we FAX nothing to him unless he has agreed
before hand." "Paul (Leber) is taking a position in talking with outside
folks today that Lilly and FDA working together on the suicide issue and
following closely the postmarketing events, but that there are no
denominators and the best that can be done is to put a 'cap' on the number
of events." Exhibit 104 (top of 1st page and bottom of 2nd page)

15) August 3, 1990 - Letter to sales representatives regarding reports of
suicidal ideation/behavior possibly associated with PROZAC therapy. "This
information is not intended to replace our current promotional strategy but
is being provided to enable you to respond to physicians when appropriate.
You should not initiate discussion on these issues nor use this letter in
detailing. However, if asked to comment on these issues by a health care
professional, you should: 1. Reassure the health care professional that no
casual relationship has been established between suicidal ideation and
PROZAC therapy." Exhibit 17 (bottom of 1st page and top of 2nd page)

16) August 31, 1990 - "Dear Doctor" letter assuring them that there is no
"causal relationship between Prozac and suicidality (ideation or acts)."
Exhibit 22

17) September 12, 1990 - Lilly memo between Max Talbot and Leigh Thompson-
Talbot says "One possible strategy if FDA presses for an additional labeling
change vis-a-vis suicide is a class-wide (i.e. ALL antidepressants)
cautionary note; however we should take this position only as a last
resort." Thompson replies: "that report MUST move swiftly through approval
and to Dr. Leber's (FDA) hands - - he is our defender." Exhibit 109

18) September 14, 1990 - Lilly memo between John Heiligenstein (Lilly) and
Leigh Thompson - Heiligenstein says: "We feel caution should be exercised in
a statement that "suicidality and hostile acts in patients taking Prozac
reflect the patient's disorder and not a causal relationship to
Prozac - - - - Postmarketing reports are increasingly fuzzy and we have
assigned 'Yes, reasonably related' on several reports.". . . "You may want
to note that trials were not intended to address issue of suicidality."
Exhibit 110

19) September 25, 1990 - Minutes of Lilly Meeting with FDA - discuss doing
an in-hospital rechallenge of patients who met predefined criteria for
suicidal acts and ideation and agrees to "analyze international data
relating to suicide." Exhibit 112

20) October 2, 1990 - Memo to Lilly employee Leigh Thompson to Lilly
employee Robert Zerbe regarding an upcoming Prozac symposium in which the
issue of suicidality is discussed. "Then the question is what to do with the
'big' numbers on suicidality. If the report numbers are shown next to those
for nausea, they seem small." Exhibit 113 (2nd page.)

21) November 7, 1990 - Leigh Thompson memo - "I'd suggest that priorities
are: (1) protect Prozac" . . . Exhibit 116

22) November 13, 1990 - Memo from Claude Bouchy (Lilly Germany) to Leigh
Thompson Re: Adverse Drug Event Reporting - Suicide Fluoxetine - In response
to Lilly's request that he (Bouchy) change the event "suicidal ideation" to
"depression," Bouchy writes: "Hans (another Lilly employee in Germany) has
medical problems with these directions and I have great concerns about it. I
do not think I could explain to the BGA, a judge, to a reporter or even to
my family why we would do this especially on the sensitive issue of suicide
and suicidal ideation." Exhibit 117

23) November 14, 1990 - Second memo from Claude Bouchy (Lilly Germany) to
Leigh Thompson Re: Adverse Drug Event Reporting - Suicide Fluoxetine in
which he states: "I personally wonder whether we are really helping the
credibility of an excellent ADE system by calling overdose what a physician
reports as suicide attempt and by calling depression what a physician is
reporting as suicide ideation." Exhibit 118

24) April 15, 1991 - Memo to Leigh Thompson called "Upcoming TV appearance"
Section I. "MESSAGE GOALS - Whatever questions you are asked or direction
the interview take, the three points we want to establish are: 2. 'It's in
the disease, not the drug.'; Section III 'If pressed, or as a postscript to
the above, then make the point that absolutely no evidence indicates that
PROZAC as a cause of such behavior (violence and suicide).', and 'Prozac
defense . . . There is simply no medical or scientific merit to the
argument." Exhibit 123

25) April 23, 1991 - Leigh Thompson Memo re 20/20 Show in which he admits
that on the issue of suicidality "I did NOT share the European data AT ALL."
and "She attacked on us hiding data by dividing up reports by many COSTART
terms. She had numbers for suicide, overdose, intentional overdose,
unintentional overdose and said they came to 1200 (or 1400) total
suicides - - so we went around on OD not necessarily being suicide and
COSTART, etc." Exhibit 124 (bottom of 1st page and 4th paragraph of 2nd
page)

26) May 15, 1991 - FDA Meeting to Discuss Fluoxetine Rechallenge Protocol -
"we agreed to have the rechallenge protocol ready to go by September 1, 1991
Exhibit 125

27) August 1991 - Dr. David Healy's Article "Antidepressant Induced Suicidal
Ideation" - "These two cases suggest that the emergence of suicidal ideation
on antidepressants cannot always be attributed to a lifting of psychomotor
retardation but rather that the ideas may in some instances be produced by
antidepressants." Exhibit 126

28) October 29, 1991 - Lilly prepared draft for Dr. Beasley entitled
"Suggested Reply Points to Oswald, Healy & Creaney" in which he acknowledges
that item 3 of the HAMD is an insensitive measure of suicidality and
states:"There was no specific rating scale for akathisia included in the
trial designs for the studies reported, so the only source of data would be
adverse event reports. Akathisia is a subjective phenomenon and hence would
rely on patients volunteering information." Exhibit 130 (2nd page)

29) December 1991 - Dr. Rothschild's Article "Re-exposure to Fluoxetine
After Serious Suicide Attempts by Three Patients: The Role of Akathisia" -
"This is the first report, to our knowledge, of patients restarted on
fluoxetine (Prozac) after a previous suicide attempt during fluoxetine
treatment." . . ."When re-exposed to fluoxetine, the patients again
developed akathisia and suicidal ideation. The suicidal feelings abated when
the akathisia was treated by the discontinuation of the fluoxetine (Prozac)
or the addition of propranolol." Exhibit 131 (Cross-examination)

30) January 23, 1992 - Lilly memo regarding upcoming meeting with Taiwanese
doctors (Drs. Lu and Ko) to discuss the report on their study results
entitled "suicidal attempts and fluoxetine (Prozac) treatment." Exhibit 133

31) April 8, 1992 - Weinstein (Lilly employee) Report - "Mission
Accomplished. Professor Lu will not present or publish his fluoxetine
(Prozac) vs. maprotiline suicidality data." Exhibit 144

32) March 3, 1993 - Forsyth's deaths

33) 1994 - Dr. David Healy's Article "The Fluoxetine and Suicide
Controversy" - Dr. Healy concludes: "In the opinion of this author, the
volume of case reports and other studies is sufficient to demonstrate that
antidepressants and antipsychotics may induce suicidal ideation in certain
individuals under certain conditions." Exhibit 153

34) 1995 - Dr. Jick's Study "Antidepressants and Suicide" - "The results
indicate that only fluoxetine (Prozac) has a rate that seems to be
substantially higher than that of the other antidepressants." Exhibit 155

35) June 1998 - Dr. Roger Lane's article "SSRI-Induced Extrapyramidal
Side-Effects and Akathisia; Implications for Treatment" appears in the
Journal of Psychopharmacology. "SSRI-induced akathisia is a relatively rare
but is frequently unrecognized when it does occur." . . . "The precise
definition of akathisia is a matter of controversy, as is the relative
importance of the objective and subjective aspects of the disorder. Is
akathisia a movement disorder or an intense and uncomfortable mental state .
.. ." "It may be less of a question of patients experiencing fluoxetine
(Prozac)-induced suicidal ideation, than patients feeling that 'death is a
welcome result' when the acutely discomforting symptoms of akathisia are
experienced on top of already distressing disorders."
===============================
For starters.